EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Video and podcast roundups

What must be updated before relying on older compounding recordings?

Dose Diligence research deskSection 07 · Page 6 of 9Last updated 17 Nov 2026

Use recordings to organise questions; use current primary material to evaluate the proposed arrangement. Three developments are particularly relevant to interpreting this shortlist:

  1. A prescription or added ingredient is not automatic permission. FDA’s April 1, 2026 clarification describes the 503A patient-specific prescription condition alongside restrictions on essentially copying commercially available drugs. Its examples include semaglutide combined with vitamin B12. The same page explains separate 503B bulk-substance conditions and states that semaglutide and tirzepatide are not on the relevant shortage or 503B bulks lists. FDA clarification. (fda.gov)

  2. Individualised-difference documentation is being examined in practice. In its September 18, 2026 warning letter to Empower’s identified 503A facility, FDA challenged missing and repeated prescriber-difference statements, including concerns about pre-generated language. This is FDA’s position in a particular enforcement letter—not a court ruling about every compounding arrangement. Warning letter. (fda.gov)

  3. Marketing language belongs in supplier diligence. FDA warns against presenting compounded products as approved generics or equivalent approved medicines, obscuring the actual compounder, or claiming an FDA-approved or FDA-licensed pharmacy. FDA does not approve or license facilities. FDA telehealth marketing reminders. (fda.gov)

This is not an exhaustive litigation, enforcement or state-law review. Obtain a dated, product- and arrangement-specific assessment before making commitments.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. fda.gov · Source 2 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs
Section sources →